Medidata Solutions Inc. (MDSO) PT Raised to $46.00
Medidata Solutions Inc. (NASDAQ:MDSO) had its price target hoisted by research analysts at Jefferies Group from $41.00 to $46.00 in a note issued to investors on Tuesday. The firm presently has an “underperform” rating on the stock. Jefferies Group’s price objective would suggest a potential downside of 16.71% from the company’s previous close.
A number of other equities research analysts have also issued reports on MDSO. Deutsche Bank AG upped their target price on shares of Medidata Solutions from $56.00 to $58.00 and gave the company a “buy” rating in a research note on Tuesday, September 13th. TheStreet upgraded shares of Medidata Solutions from a “hold” rating to a “buy” rating in a research note on Thursday, August 25th. Morgan Stanley restated a “buy” rating and issued a $61.00 target price on shares of Medidata Solutions in a research note on Thursday, August 25th. Finally, Zacks Investment Research upgraded shares of Medidata Solutions from a “hold” rating to a “buy” rating and set a $54.00 target price on the stock in a research note on Tuesday, November 1st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $54.80.
Medidata Solutions (NASDAQ:MDSO) opened at 55.23 on Tuesday. The stock has a market cap of $3.08 billion, a price-to-earnings ratio of 126.10 and a beta of 1.49. The company’s 50 day moving average price is $51.53 and its 200-day moving average price is $50.74. Medidata Solutions has a 12-month low of $30.22 and a 12-month high of $57.85.
Medidata Solutions (NASDAQ:MDSO) last issued its quarterly earnings data on Tuesday, October 25th. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of $0.26 by $0.02. Medidata Solutions had a net margin of 5.70% and a return on equity of 10.46%. The firm had revenue of $120.10 million for the quarter, compared to analyst estimates of $118.96 million. During the same quarter in the previous year, the business posted $0.25 EPS. The firm’s revenue was up 16.5% compared to the same quarter last year. On average, analysts forecast that Medidata Solutions will post $1.02 EPS for the current year.
In other Medidata Solutions news, CEO Tarek Sherif sold 7,500 shares of the company’s stock in a transaction dated Wednesday, November 2nd. The shares were sold at an average price of $46.70, for a total value of $350,250.00. Following the completion of the transaction, the chief executive officer now owns 814,580 shares in the company, valued at approximately $38,040,886. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Eileen Schloss sold 3,831 shares of the company’s stock in a transaction dated Wednesday, November 16th. The stock was sold at an average price of $56.60, for a total transaction of $216,834.60. Following the completion of the transaction, the executive vice president now owns 33,561 shares of the company’s stock, valued at approximately $1,899,552.60. The disclosure for this sale can be found here. 6.70% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of MDSO. Acrospire Investment Management LLC boosted its position in Medidata Solutions by 90.0% in the third quarter. Acrospire Investment Management LLC now owns 1,900 shares of the company’s stock valued at $106,000 after buying an additional 900 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Medidata Solutions by 13.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,978 shares of the company’s stock worth $110,000 after buying an additional 227 shares in the last quarter. LS Investment Advisors LLC raised its stake in shares of Medidata Solutions by 9.2% in the second quarter. LS Investment Advisors LLC now owns 2,411 shares of the company’s stock worth $113,000 after buying an additional 203 shares in the last quarter. Pacer Advisors Inc. bought a new stake in shares of Medidata Solutions during the third quarter worth $191,000. Finally, Tower Research Capital LLC TRC raised its stake in shares of Medidata Solutions by 5.3% in the second quarter. Tower Research Capital LLC TRC now owns 3,498 shares of the company’s stock worth $164,000 after buying an additional 177 shares in the last quarter. Hedge funds and other institutional investors own 99.63% of the company’s stock.
About Medidata Solutions
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Medidata Clinical Cloud provides a platform of technology and data analytics solutions designed to manage activities across clinical development.
Receive News & Stock Ratings for Medidata Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions Inc. and related stocks with our FREE daily email newsletter.